Reaction Biology Acquires Bioassay GmbH for Increasing Large Molecule Capabilities
In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.
Reaction Biology Corporation announced on December 2, 2022 that their closure on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH (Bioassay GmbH), including its wholly owned subsidiary, Peptide Specialty Laboratories GmbH (PSL), located in Heidelberg, Germany.
Bioassay offers good manufacturing practices (GMP)-accredited potency assays and functional bioassays, good laboratory practices (GLP)-compliant services, and through PSL, peptide synthesis services, including peptide-specific antibody production and neoantigen synthesis.
In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.
“Market demand is increasing globally for large-molecule services as biopharmaceutical companies search for new treatment options for patients suffering with cancer and other serious diseases,” said John H. Johnson, chief executive officer of Reaction Biology, in a press release. “This transaction enables Reaction Biology to add Bioassay GmbH’s impressive clinical phase and post-approval infrastructure, which includes large molecule capabilities, as well as its GMP and GLP accreditations, to our expanding suite of drug discovery and development services. We can now provide our customers with even broader offerings to meet their research and development goals.”
Source: Reaction Biology
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
